Frankfurt - Delayed Quote EUR

Agios Pharmaceuticals, Inc. (8AP.F)

29.40 +0.40 (+1.38%)
At close: April 26 at 8:25 AM GMT+2
Key Events
Advanced Chart
Loading Chart for 8AP.F
DELL
  • Previous Close 29.00
  • Open 29.40
  • Bid 29.00 x 20000
  • Ask 29.60 x 20000
  • Day's Range 29.40 - 29.40
  • 52 Week Range 18.80 - 31.80
  • Volume 200
  • Avg. Volume 9
  • Market Cap (intraday) 1.652B
  • Beta (5Y Monthly) 0.86
  • PE Ratio (TTM) --
  • EPS (TTM) -5.90
  • Earnings Date May 2, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 62.43

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

www.agios.com

383

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Agios Pharmaceuticals, Inc.

Recent News: 8AP.F

View More
View More

Performance Overview: 8AP.F

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

8AP.F
44.12%
S&P 500
6.92%

1-Year Return

8AP.F
47.00%
S&P 500
25.26%

3-Year Return

8AP.F
35.96%
S&P 500
22.00%

5-Year Return

8AP.F
41.86%
S&P 500
74.29%

Compare To: 8AP.F

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

8AP.F
Agios Pharmaceuticals, Inc.
29.40
+1.38%
Mkt Cap EUR 1.652B
Industry Biotechnology
47N.BE
Citius Pharmaceuticals Inc
0.6090
-8.56%
Mkt Cap EUR -
Industry Biotechnology
0A9E.IL
CureVac N.V.
2.2840
+0.84%
Mkt Cap 570.518M
Industry Biotechnology
EXAI
Exscientia plc
4.0300
+1.00%
Mkt Cap 509.291M
Industry Biotechnology

Statistics: 8AP.F

View More

Valuation Measures

Annual
As of 4/28/2024

  • Market Cap

    1.65B

  • Enterprise Value

    992.43M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    65.44

  • Price/Book (mrq)

    2.19

  • Enterprise Value/Revenue

    37.00

  • Enterprise Value/EBITDA

    -2.58

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -22.49%

  • Return on Equity (ttm)

    -36.83%

  • Revenue (ttm)

    26.82M

  • Net Income Avi to Common (ttm)

    -352.09M

  • Diluted EPS (ttm)

    -5.90

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    776.93M

  • Total Debt/Equity (mrq)

    8.88%

  • Levered Free Cash Flow (ttm)

    -215.06M

View More

Research Analysis: 8AP.F

View More

Analyst Price Targets

39.00
62.43 Average
29.40 Current
93.00 High
 

Earnings

Consensus EPS
 
View More

Company Insights: 8AP.F

People Also Watch

RV7.F Halozyme Therapeutics, Inc.
35.95
-0.64%
 
2L9.F Blueprint Medicines Corporation
86.86
+4.60%
 
NB3.F Neurocrine Biosciences, Inc.
128.25
-0.27%
 
DUL.F Alnylam Pharmaceuticals, Inc.
133.25
+0.23%
 
ICY.F Incyte Corporation
47.59
+1.02%
 
0A3.F NEPI Rockcastle N.V.
5.60
+0.90%
 
UP0.F Ultragenyx Pharmaceutical Inc.
40.80
+0.49%
 
NKB2.F TG Therapeutics, Inc.
12.98
+1.66%
 
SG7.F Sage Therapeutics, Inc.
12.72
-3.09%
 
DR6.F ACADIA Pharmaceuticals Inc.
15.18
-0.72%
 
ITH.F Nektar Therapeutics
1.2110
-5.09%
 
AB3A.F Sarepta Therapeutics, Inc.
118.60
+3.04%
 
EX9.F Exelixis, Inc.
21.85
+0.28%
 
J7Z.F Jazz Pharmaceuticals plc
101.40
+1.44%
 
ISI.F Ionis Pharmaceuticals, Inc.
39.02
-0.86%
 
8AK.F Alkermes plc
22.60
0.00%